B. Riley raised the firm’s price target on Capricor Therapeutics (CAPR) to $50 from $21 and keeps a Buy rating on the shares. The clinical data ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Treatment with deramiocel led to a 54% slowing of upper limb function deterioration and a 91% slowing of cardiac function deterioration compared with placebo. Topline data were announced from a phase ...

A study of aging mice showed that voluntary exercise over 30 days increased striatal dopamine release and improved motor ...

Fintel reports that on December 8, 2025, Oppenheimer maintained coverage of Capricor Therapeutics (NasdaqCM:CAPR) with a ...

Capricor Therapeutics shares gained after analysts said they believe the company can achieve profitability by 2028. The stock rose 8.4% to $29.14 and hit its 52-week high of $14.87 earlier in the ...

Investor Martin Shkreli's big biotech short position is blowing up after the stock's monumental rally over the past week.

Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing of its underwritten public offering of 6, ...

Martin Shkreli says QCLS stock could hit $100 in the near-term. He has fairly recently been proven wrong on Capricor Therapeutics.

Piper Sandler and Oppenheimer & Co. are acting as the joint book-running managers for the proposed public offering. The Company intends to use the net proceeds from the proposed offering for the ...